GlassScriptPhysician profile
Jeffrey Leitman
NPI 1952448797
$2,715.72
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $272 · 2021: $538 · 2022: $769 · 2023: $285 · 2024: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $478.15 | 2019-2022 | |
| Abbvie INC. | $330.55 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $257.14 | 2019-2021 | |
| Qol Medical, LLC | $204.01 | 2020-2023 | Sucraid |
| Amarin Pharma, INC. | $186.98 | 2019-2022 | |
| Glaxosmithkline, LLC. | $143.28 | 2020-2024 | Trelegy Ellipta, Shingrix |
| Regeneron Healthcare Solutions, INC. | $137.35 | 2019 | |
| Novo Nordisk INC | $137.19 | 2019-2023 | Wegovy |
| Vertical Pharmaceuticals, LLC | $130.42 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.72 | 2019-2023 | Jardiance |
| Intercept Pharmaceuticals, INC. | $70.95 | 2021-2023 | Ocaliva |
| Biohaven Pharmaceutical Holding Company LTD. | $58.26 | 2022 | |
| Genentech USA, INC. | $50.46 | 2019-2021 | |
| Esperion Therapeutics, INC. | $41.10 | 2022 | |
| Ferring Pharmaceuticals INC. | $36.93 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $35.05 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $27.62 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $24.86 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.17 | 2021 | |
| Neurocrine Biosciences, INC. | $22.03 | 2021 | |
| Pfizer INC. | $21.57 | 2023 | |
| Lilly USA, LLC | $21.40 | 2023 | Mounjaro |
| Xeris Pharmaceuticals, INC. | $21.40 | 2022 | |
| Genzyme Corporation | $19.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.90 | 2021 | |
| Redhill Biopharma INC. | $17.81 | 2022 | |
| Vivus LLC | $17.11 | 2019 | |
| Medicomp INC | $16.72 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.10 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.02 | 2023 | Breztri |
| Bausch Health US, LLC | $12.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Leitman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.